Skip to main content
. Author manuscript; available in PMC: 2023 Jan 6.
Published in final edited form as: Mod Pathol. 2021 Sep 20;35(3):333–343. doi: 10.1038/s41379-021-00896-6

Table 1.

Clinicopathologic Characteristics of LOT Cases in the Cohort

Patient ID Age Sex Presentation Family History Other Significant Medical History Original Diagnosis Nephrectomy Laterality Tumor Size (cm) Focality (number) pT pN Stage Metastasis Follow-up (months)
LOT 1 79 F Back pain None Contralateral metastatic ccRCC ChRCC-eo Partial Right 7.8 Unifocal pT2a pNx II No Deceased (26)
LOT 2 86 F Incidental None None ChRCC-eo Radical Right 6.5 Unifocal pT1b pNx I No ALF (3)
LOT 3a 63 F Anemia Father with b/l Nx for unknown reason B/l multiple LOTs ChRCC-eo Partial Right 4.0, 2.3, 1.5, 1.4, 0.8, 0.5 Multifocal (6) pT1a* pNx I No ALF (37)
LOT 3b ChRCC-eo Partial Left 5.3, 5.2, 4.9, 3.7, 2.1, 2.0, 1.9, 1.6, 1.0, 0.9 Multifocal (10) pT1b* pNx I No
LOT 4 69 M Hematuria None None ChRCC-eo Partial Right 2.3 Unifocal pT1a pNx I No ALF (29)
LOT 5 71 F Incidental None Prior contralateral nephrectomy for benign tumor ChRCC-eo Partial Right 3.8 Unifocal pT1a pNx I No ALF (53)
LOT 6 75 F Incidental None None ChRCC-eo Partial Left 2.4 Unifocal pT1a pNx I No Deceased (36)
LOT 7 84 M Incidental None Contralateral renal mass followed with AS ChRCC-eo Radical Right 6.5 Unifocal pT1b pNx I No Deceased (29)

ccRCC: clear cell renal cell carcinoma; B/l: bilateral; Nx: nephrectomy; AS: active surveillance; ChRCC-eo: chromophobe renal cell carcinoma, eosinophilic variant

*

: pT represents the highest stage

ALF: alive at last follow-up.